Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20 (P7-9.016)

Mario Vukic, Kettia Alusma-Hibbert, Amro Stino, Simon Oh, Jamie Aldridge

原始摘要（英文原文）· Original abstract

To report expert insight on transitioning patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from intravenous immunoglobulin (IVIg) to subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20).

读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Impact of Subcutaneous Efgartigimod PH20 on Treatment-naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the ADHERE Trial: Post Hoc Analyses (P1-9.002)
How do I transition oncology patients from intravenous immunoglobulin to subcutaneous immunoglobulin in an outpatient clinic?
Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).
Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.